VC005 tablets for adults with active ankylosing spondylitis
Official title: A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis
Run by Jiangsu vcare pharmaceutical technology co., LTD · NCT07172360 · Data updated 2026-11-12
This Phase III trial will test whether VC005 tablets are safe and help reduce symptoms in adults with active ankylosing spondylitis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 420 (estimated) |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | December 26, 2025 |
| Main results expected | August 30, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT07172360 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 diagnosed with active ankylosing spondylitis by the 1984 New York criteria who can consent and follow study procedures are ideal candidates.
✕Probably not a fit
People with known allergy to VC005 or its ingredients, those who need ongoing immunosuppressants after organ transplant, or individuals the investigator deems unsuitable are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, randomized, double-blind, placebo-controlled Phase III trial comparing VC005 tablets to placebo in adults with active ankylosing spondylitis. Eligible participants aged 18–70 who meet the 1984 New York Revised Criteria are randomized to receive VC005 or matching placebo and followed for safety and efficacy endpoints. The trial uses standardized clinical assessments and safety monitoring to measure symptom improvement and adverse events. The study is sponsored by Jiangsu vcare pharmaceutical technology and includes at least one site at Peking University People's Hospital.
Why it matters
Potential benefit: If successful, VC005 could offer an additional oral treatment option that reduces inflammation and symptoms in people with active ankylosing spondylitis.
How similar studies have gone: Other oral agents and biologic therapies have shown benefit in ankylosing spondylitis, but VC005 itself has not yet published phase III results to confirm similar success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; * The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; * The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis Exclusion Criteria: * Those who may be allergic to VC005, similar drugs or their excipients. * Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants. * Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Zhanguo Li — Peking University People's Hospital
- Study coordinator: xiaojuan lai
- Email: lai_xiaojuan@vcarepharmatech.com
- Phone: 15358160458
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring the safety and effectiveness of Xeljanz XR in patients with certain types of arthritis
This study is testing how safe and effective the medication Xeljanz XR is for people in Korea with certain types of arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
-
VC005 tablets in teens with severe alopecia areata
This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.
-
VC005 tablets in severe alopecia areata
This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.
-
VC005 gel in adults with mild to moderate atopic dermatitis
This study tests whether VC005 gel works better than a placebo gel for adults with mild to moderate atopic dermatitis.
-
VC005 for adults and teens with mild to moderate atopic dermatitis
This study tests VC005 versus placebo to see if it helps people 12 and older with mild to moderate atopic dermatitis.
-
VC005 tablets for people with non-segmental vitiligo
This trial will test VC005 tablets to see if they safely help adults aged 18–70 with non-segmental vitiligo regain skin pigment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.